Immunosuppressive glycoforms of soluble CD52

Leonard Charles Harrison; Esther Bandala-Sanchez; Ethan David Goddard-Borger; Nicolle Hannah Packer; Shathili Abdulrahman Mansour

Immunosuppressive glycoforms of soluble CD52

Leonard Charles Harrison (Inventor), Esther Bandala-Sanchez (Inventor), Ethan David Goddard-Borger (Inventor), Nicolle Hannah Packer (Inventor), Shathili Abdulrahman Mansour (Inventor)

Research output: Patent

Abstract

The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has α-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.

Original language	English
Patent number	WO2020176921
IPC	C07K 9/00 2006.1,C07K 1/22 2006.1,C07K 1/18 2006.1,A61P 37/00 2006.1,A61K 38/04 2006.1
Priority date	7/03/19
Publication status	Submitted - 10 Sept 2020

Bibliographical note

Designated States:
AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)

Access to Document

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020176921

2 Patent

Immunosuppressive glycoforms of soluble CD52
Harrison, L. C. (Inventor), Bandala-Sanchez, E. (Inventor), Goddard-Borger, E. D. (Inventor), Packer, N. H. (Inventor) & Mansour, S. A. (Inventor), 12 Jan 2022, (Submitted) IPC No. C07K 9/00, A61K 38/00, A61K 38/04, A61P 37/00, C07K 1/18, C07K 1/22, Patent No. EP3935073, Priority date 7 Mar 2019, Priority No. WO2019AU50197
Research output: Patent
Immunosuppressive glycoforms of soluble CD52
Harrison, L. C. (Inventor), Bandala-Sanchez, E. (Inventor), Goddard-Borger, E. D. (Inventor), Packer, N. H. (Inventor) & Shathili, A. (Inventor), 19 Mar 2020, IPC No. C07K 4/12, A61K 38/00, A61K 38/10, A61K 39/00, A61P 29/00, A61P 37/00, Patent No. AU2019201584, 7 Mar 2019, Priority date 7 Mar 2019
Research output: Patent

Cite this

@misc{9a1f69f2650c46849d6780e781157cd2,

title = "Immunosuppressive glycoforms of soluble CD52",

abstract = "The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has α-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.",

author = "Harrison, \{Leonard Charles\} and Esther Bandala-Sanchez and Goddard-Borger, \{Ethan David\} and Packer, \{Nicolle Hannah\} and Mansour, \{Shathili Abdulrahman\}",

note = "Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW) Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM) European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR) African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG); WO2020176921; C07K 9/00 2006.1,C07K 1/22 2006.1,C07K 1/18 2006.1,A61P 37/00 2006.1,A61K 38/04 2006.1",

year = "2020",

month = sep,

day = "10",

language = "English",

type = "Patent",

}

TY - PAT

T1 - Immunosuppressive glycoforms of soluble CD52

AU - Harrison, Leonard Charles

AU - Bandala-Sanchez, Esther

AU - Goddard-Borger, Ethan David

AU - Packer, Nicolle Hannah

AU - Mansour, Shathili Abdulrahman

N1 - Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW) Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM) European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR) African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)

PY - 2020/9/10

Y1 - 2020/9/10

N2 - The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has α-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.

AB - The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has α-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.

M3 - Patent

M1 - WO2020176921

ER -

Immunosuppressive glycoforms of soluble CD52

Abstract

Bibliographical note

Access to Document

Fingerprint

Research output